Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is Sector Gamma AS's 9th Largest Position

Sector Gamma AS trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 11.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 141,218 shares of the medical equipment provider's stock after selling 17,851 shares during the period. Zimmer Biomet makes up 4.2% of Sector Gamma AS's portfolio, making the stock its 9th biggest holding. Sector Gamma AS owned approximately 0.07% of Zimmer Biomet worth $17,186,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. American Century Companies Inc. lifted its stake in shares of Zimmer Biomet by 21.2% in the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider's stock valued at $545,809,000 after buying an additional 852,186 shares during the period. Victory Capital Management Inc. lifted its stake in shares of Zimmer Biomet by 4.9% in the third quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider's stock valued at $345,690,000 after buying an additional 144,147 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Zimmer Biomet by 16.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,760,021 shares of the medical equipment provider's stock valued at $335,895,000 after buying an additional 386,019 shares during the period. Boston Partners lifted its stake in shares of Zimmer Biomet by 29.2% in the third quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider's stock valued at $302,366,000 after buying an additional 608,959 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Zimmer Biomet by 4.5% in the third quarter. Northern Trust Corp now owns 2,653,334 shares of the medical equipment provider's stock valued at $297,757,000 after buying an additional 113,139 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Down 0.3 %

Shares of NYSE:ZBH traded down $0.40 during midday trading on Friday, reaching $119.35. 1,099,241 shares of the company were exchanged, compared to its average volume of 1,046,552. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The stock has a fifty day simple moving average of $125.98 and a two-hundred day simple moving average of $119.57. The firm has a market cap of $24.52 billion, a PE ratio of 24.41, a P/E/G ratio of 2.20 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts' consensus estimates of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same period last year, the business posted $1.88 earnings per share. The firm's quarterly revenue was up 6.3% on a year-over-year basis. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. Zimmer Biomet's payout ratio is 19.63%.

Insider Buying and Selling

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.95% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ZBH shares. Evercore ISI increased their target price on shares of Zimmer Biomet from $125.00 to $130.00 and gave the company an "in-line" rating in a research note on Thursday, April 4th. Citigroup increased their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 3rd. JPMorgan Chase & Co. increased their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a "neutral" rating in a research report on Friday, February 9th. Truist Financial increased their price target on shares of Zimmer Biomet from $133.00 to $135.00 and gave the stock a "hold" rating in a research report on Friday, February 9th. Finally, TheStreet raised shares of Zimmer Biomet from a "c" rating to a "b-" rating in a research report on Thursday, February 8th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and an average price target of $139.39.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.